• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

复发缓解型多发性硬化的继发进展期转换:定义和危险因素。

Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.

机构信息

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro," Bari, Italy.

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro," Bari, Italy/Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.

出版信息

Mult Scler. 2021 Mar;27(3):430-438. doi: 10.1177/1352458520974366. Epub 2020 Nov 19.

DOI:10.1177/1352458520974366
PMID:33210986
Abstract

BACKGROUND

No uniform criteria for a sensitive identification of the transition from relapsing-remitting multiple sclerosis (MS) to secondary-progressive multiple sclerosis (SPMS) are available.

OBJECTIVE

To compare risk factors of SPMS using two definitions: one based on the neurologist judgment (ND) and an objective data-driven algorithm (DDA).

METHODS

Relapsing-onset MS patients ( = 19,318) were extracted from the Italian MS Registry. Risk factors for SPMS and for reaching irreversible Expanded Disability Status Scale (EDSS) 6.0, after SP transition, were estimated using multivariable Cox regression models.

RESULTS

SPMS identified by the DDA ( = 2343, 12.1%) were older, more disabled and with a faster progression to severe disability ( < 0.0001), than those identified by the ND ( = 3868, 20.0%). In both groups, the most consistent risk factors ( < 0.05) for SPMS were a multifocal onset, an age at onset >40 years, higher baseline EDSS score and a higher number of relapses; the most consistent protective factor was the disease-modifying therapy (DMT) exposure. DMT exposure during SP did not impact the risk of reaching irreversible EDSS 6.0.

CONCLUSION

A DDA definition of SPMS identifies more aggressive progressive patients. DMT exposure reduces the risk of SPMS conversion, but it does not prevent the disability accumulation after the SP transition.

摘要

背景

目前尚无统一的标准来敏感识别从复发缓解型多发性硬化症(RRMS)向继发进展型多发性硬化症(SPMS)的转变。

目的

使用两种定义(一种基于神经病学家判断(ND),另一种基于客观数据驱动算法(DDA))比较 SPMS 的危险因素。

方法

从意大利多发性硬化症登记处提取了发病初即为复发型 MS 患者( = 19,318)。使用多变量 Cox 回归模型估计 SPMS 和 SP 转变后达到不可逆扩展残疾状态量表(EDSS)6.0 的风险因素。

结果

DDA 识别的 SPMS( = 2343,12.1%)比 ND 识别的 SPMS( = 3868,20.0%)年龄更大、残疾程度更高且向严重残疾进展更快( < 0.0001)。在这两组中,最一致的 SPMS 危险因素( < 0.05)是多灶性发病、发病年龄>40 岁、基线 EDSS 评分较高和复发次数较多;最一致的保护因素是疾病修正治疗(DMT)的使用。SP 期间 DMT 的使用并未影响达到不可逆 EDSS 6.0 的风险。

结论

DDA 定义的 SPMS 识别出更具侵袭性的进展性患者。DMT 的使用降低了 SPMS 转换的风险,但不能防止 SP 转变后的残疾累积。

相似文献

1
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.复发缓解型多发性硬化的继发进展期转换:定义和危险因素。
Mult Scler. 2021 Mar;27(3):430-438. doi: 10.1177/1352458520974366. Epub 2020 Nov 19.
2
Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.第一代疾病修正疗法预防继发进展型多发性硬化转归的疗效。
Mult Scler Relat Disord. 2022 Dec;68:104220. doi: 10.1016/j.msard.2022.104220. Epub 2022 Oct 5.
3
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.迈向对继发进展型多发性硬化临床转变的有效定义:一项来自意大利多发性硬化症登记处的研究
Mult Scler. 2022 Dec;28(14):2243-2252. doi: 10.1177/13524585221114007. Epub 2022 Aug 15.
4
Risk of secondary progressive multiple sclerosis after early worsening of disability.残疾早期恶化后发生继发进展性多发性硬化的风险。
J Neurol Neurosurg Psychiatry. 2023 Dec;94(12):984-991. doi: 10.1136/jnnp-2023-331748. Epub 2023 Jul 6.
5
Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.使用多水平模型对复发缓解型多发性硬化症的疾病进展进行建模,该模型应用于来自两个自然史队列和一个治疗队列的纵向数据。
Health Technol Assess. 2016 Oct;20(81):1-48. doi: 10.3310/hta20810.
6
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?疾病修正药物在延缓复发型多发性硬化症进展方面的效果如何?
Neurology. 2007 Oct 9;69(15):1498-507. doi: 10.1212/01.wnl.0000271884.11129.f3. Epub 2007 Aug 15.
7
Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.定义在丹麦全国人群中的继发进展型多发性硬化转化中的应用。
Mult Scler Relat Disord. 2021 Nov;56:103319. doi: 10.1016/j.msard.2021.103319. Epub 2021 Oct 10.
8
Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.SPECTRUM 研究结果:一项调查医疗保健专业人员以了解英国继发进展型多发性硬化症的当前诊断和管理实践。
Mult Scler Relat Disord. 2021 Oct;55:103174. doi: 10.1016/j.msard.2021.103174. Epub 2021 Jul 26.
9
Natural history of secondary-progressive multiple sclerosis.继发进展型多发性硬化的自然史。
Mult Scler. 2008 Apr;14(3):314-24. doi: 10.1177/1352458507084264. Epub 2008 Jan 21.
10
Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.继发进展型多发性硬化症诊断与管理中的方法及挑战:中东欧医疗专业人员视角
Mult Scler Relat Disord. 2021 May;50:102778. doi: 10.1016/j.msard.2021.102778. Epub 2021 Jan 28.

引用本文的文献

1
Refining Prognostic Factors in Adult-Onset Multiple Sclerosis: A Narrative Review of Current Insights.成人多发性硬化症预后因素的细化:当前见解的叙述性综述
Int J Mol Sci. 2025 Aug 11;26(16):7756. doi: 10.3390/ijms26167756.
2
Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM study.尽管早期进行了高度积极的治疗,但在多发性硬化症中进行继发性进展活动监测:SPAM研究
Eur J Neurol. 2025 May;32(5):e16583. doi: 10.1111/ene.16583.
3
Modulation of NCX1 expression in monocytes associates with multiple sclerosis progression.
单核细胞中NCX1表达的调节与多发性硬化症的进展相关。
Heliyon. 2025 Jan 30;11(4):e42332. doi: 10.1016/j.heliyon.2025.e42332. eCollection 2025 Feb 28.
4
Patterns and predictors of multiple sclerosis phenotype transition.多发性硬化症表型转变的模式与预测因素。
Brain Commun. 2024 Nov 23;6(6):fcae422. doi: 10.1093/braincomms/fcae422. eCollection 2024.
5
Multiple sclerosis: emerging epidemiological trends and redefining the clinical course.多发性硬化症:新出现的流行病学趋势及对临床病程的重新定义
Lancet Reg Health Eur. 2024 Aug 22;44:100977. doi: 10.1016/j.lanepe.2024.100977. eCollection 2024 Sep.
6
Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA).活动期和非活动期继发进展型多发性硬化症患者的残疾进展相似:一项意大利多发性硬化症注册研究(ASPERA)的结果
J Neurol. 2024 Oct;271(10):6801-6810. doi: 10.1007/s00415-024-12621-9. Epub 2024 Aug 27.
7
Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force.引入用于多发性硬化症登记处和队列研究的真实世界数据核心数据集:全球特别工作组的建议。
Mult Scler. 2024 Mar;30(3):396-418. doi: 10.1177/13524585231216004. Epub 2023 Dec 23.
8
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.评估复发型多发性硬化症治疗转换的驱动因素:来自意大利多发性硬化症注册研究。
J Neurol. 2024 Mar;271(3):1150-1159. doi: 10.1007/s00415-023-12137-8. Epub 2023 Dec 22.
9
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.继发进展型多发性硬化的发病风险具有地理差异性,但可以通过改变生活方式加以控制。
Brain. 2023 Nov 2;146(11):4633-4644. doi: 10.1093/brain/awad218.
10
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers.使用客观分类器对五个欧洲登记处中继发进展型多发性硬化症的比例及特征进行研究。
Mult Scler J Exp Transl Clin. 2023 Feb 16;9(1):20552173231153557. doi: 10.1177/20552173231153557. eCollection 2023 Jan-Mar.